Role of PI3K-AKT-mTOR and Wnt Signaling Pathways in Transition of G1-S Phase of Cell Cycle in Cancer Cells
暂无分享,去创建一个
Reddanna Pallu | Mukesh Pasupuleti | Lakshmipathi Vadlakonda | Reddanna Pallu | Mukesh Pasupuleti | Lakshmipathi Vadlakonda
[1] David R. Bowler,et al. The Nuts and Bolts , 2013 .
[2] John A Foley,et al. Nuts and bolts. , 2013, Connecticut medicine.
[3] A. Levine,et al. Proliferation and tissue remodeling in cancer: the hallmarks revisited , 2012, Cell Death and Disease.
[4] R. DePinho,et al. FOXO1 orchestrates the bone-suppressing function of gut-derived serotonin. , 2012, The Journal of clinical investigation.
[5] Charles Y. Lin,et al. Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.
[6] C. Talchai,et al. Pancreatic β Cell Dedifferentiation as a Mechanism of Diabetic β Cell Failure , 2012, Cell.
[7] K. Mahajan,et al. PI3K‐independent AKT activation in cancers: A treasure trove for novel therapeutics , 2012, Journal of cellular physiology.
[8] J. Powell,et al. All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells , 2012, Front. Immun..
[9] O. Delpuech,et al. FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression , 2011, Cell Death and Differentiation.
[10] Zhiwei Wang,et al. An evolving role for DEPTOR in tumor development and progression. , 2012, Neoplasia.
[11] Paul Polakis,et al. Wnt signaling in cancer. , 2012, Cold Spring Harbor perspectives in biology.
[12] S. Johansson,et al. Receptor-Specific Mechanisms Regulate Phosphorylation of AKT at Ser473: Role of RICTOR in β1 Integrin-Mediated Cell Survival , 2012, PloS one.
[13] C. Dessy,et al. Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. , 2012, Cancer research.
[14] Zheng Guo,et al. Rictor regulates FBXW7-dependent c-Myc and cyclin E degradation in colorectal cancer cells. , 2012, Biochemical and biophysical research communications.
[15] M. Radi,et al. ATP-competitive inhibitors of mTOR: an update. , 2011, Current medicinal chemistry.
[16] L. Pickering,et al. Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer. , 2011, Future oncology.
[17] Daniel J. Klionsky,et al. Relieving Autophagy and 4EBP1 from Rapamycin Resistance , 2011, Molecular and Cellular Biology.
[18] M. Lu,et al. Wnt/β-catenin signaling accelerates mouse lung tumorigenesis by imposing an embryonic distal progenitor phenotype on lung epithelium. , 2011, The Journal of clinical investigation.
[19] Carlos A. Garcia,et al. Convergence of the Mammalian Target of Rapamycin Complex 1- and Glycogen Synthase Kinase 3-β–Signaling Pathways Regulates the Innate Inflammatory Response , 2011, The Journal of Immunology.
[20] C. Weihl. Valosin containing protein associated fronto-temporal lobar degeneration: clinical presentation, pathologic features and pathogenesis. , 2011, Current Alzheimer research.
[21] J. McCubrey,et al. Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia , 2011, Leukemia.
[22] Randy L. Johnson,et al. Hippo Pathway Inhibits Wnt Signaling to Restrain Cardiomyocyte Proliferation and Heart Size , 2011, Science.
[23] E. E. Vincent,et al. Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer , 2011, British Journal of Cancer.
[24] E. Goncharova,et al. mTORC2 Is Required for Proliferation and Survival of TSC2-Null Cells , 2011, Molecular and Cellular Biology.
[25] R. Hajjar,et al. Resistin Promotes Cardiac Hypertrophy via the AMP-activated Protein Kinase/Mammalian Target of Rapamycin (AMPK/mTOR) and c-Jun N-terminal Kinase/Insulin Receptor Substrate 1 (JNK/IRS1) Pathways* , 2011, The Journal of Biological Chemistry.
[26] G. Condorelli,et al. IκB kinase ε and TANK-binding kinase 1 activate AKT by direct phosphorylation , 2011, Proceedings of the National Academy of Sciences.
[27] V. Deretic. Autophagy in immunity and cell‐autonomous defense against intracellular microbes , 2011, Immunological reviews.
[28] E. Gottlieb. p53 guards the metabolic pathway less travelled , 2011, Nature Cell Biology.
[29] A. Mancuso,et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase , 2011, Nature Cell Biology.
[30] C. Eng,et al. Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling. , 2011, Cancer letters.
[31] Karen H. Vousden,et al. Metabolic regulation by p53 , 2011, Journal of Molecular Medicine.
[32] Chien-Hung Chen,et al. ER Stress Inhibits mTORC2 and Akt Signaling Through GSK-3β–Mediated Phosphorylation of Rictor , 2011, Science Signaling.
[33] B. Viollet,et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1 , 2011, Nature Cell Biology.
[34] Yongqiang Chen,et al. The regulation of autophagy – unanswered questions , 2011, Journal of Cell Science.
[35] D. Steiner,et al. GSK-3 inactivation or depletion promotes β-cell replication via down regulation of the CDK inhibitor, p27 (Kip1) , 2011, Islets.
[36] Stuart H. Orkin,et al. A Myc Network Accounts for Similarities between Embryonic Stem and Cancer Cell Transcription Programs , 2010, Cell.
[37] D. Klionsky,et al. Eaten alive: a history of macroautophagy , 2010, Nature Cell Biology.
[38] Xu Zhang,et al. Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation , 2010, Nature Cell Biology.
[39] Novel inhibitors of mTORC1 and mTORC2. , 2010, Current opinion in investigational drugs.
[40] V. De Pinto,et al. VDAC, a multi-functional mitochondrial protein regulating cell life and death. , 2010, Molecular aspects of medicine.
[41] Ye Guang Chen,et al. Dishevelled: The hub of Wnt signaling. , 2010, Cellular signalling.
[42] N. Hay,et al. FoxOs inhibit mTORC1 and activate Akt by inducing the expression of Sestrin3 and Rictor. , 2010, Developmental cell.
[43] A. Marette,et al. Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes. , 2010, Molecular endocrinology.
[44] D. Sabatini,et al. Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids , 2010, Cell.
[45] M. Magnuson,et al. Fat Cell–Specific Ablation of Rictor in Mice Impairs Insulin-Regulated Fat Cell and Whole-Body Glucose and Lipid Metabolism , 2010, Diabetes.
[46] Mark H. Ellisman,et al. Sestrin as a Feedback Inhibitor of TOR That Prevents Age-Related Pathologies , 2010, Science.
[47] Dianqing Wu,et al. GSK3: a multifaceted kinase in Wnt signaling. , 2010, Trends in biochemical sciences.
[48] J. Downward,et al. Rictor is a novel target of p70 S6 kinase-1 , 2010, Oncogene.
[49] Cam Patterson,et al. The FoxO family in cardiac function and dysfunction. , 2010, Annual review of physiology.
[50] M. Swami. MYC matters. , 2010, Nature reviews. Cancer.
[51] D. Alessi,et al. The nuts and bolts of AGC protein kinases , 2010, Nature Reviews Molecular Cell Biology.
[52] Philippe P Roux,et al. mTORC1-Activated S6K1 Phosphorylates Rictor on Threonine 1135 and Regulates mTORC2 Signaling , 2009, Molecular and Cellular Biology.
[53] B. Burgering,et al. Should I stay or should I go: beta-catenin decides under stress. , 2009, Biochimica et biophysica acta.
[54] M. Stipanuk. Macroautophagy and its role in nutrient homeostasis. , 2009, Nutrition reviews.
[55] R. Abraham,et al. Targeting mTOR globally in cancer: Thinking beyond rapamycin , 2009, Cell cycle.
[56] D. Sabatini,et al. mTOR signaling at a glance , 2009, Journal of Cell Science.
[57] J. Asara,et al. Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1 , 2009, Molecular and Cellular Biology.
[58] R. Lothe,et al. Autophagy in tumour suppression and promotion , 2009, Molecular oncology.
[59] Mina J Bissell,et al. Interaction of E-cadherin and PTEN regulates morphogenesis and growth arrest in human mammary epithelial cells. , 2009, Cancer research.
[60] J. Blenis,et al. Molecular mechanisms of mTOR-mediated translational control , 2009, Nature Reviews Molecular Cell Biology.
[61] Simon Tavaré,et al. Autophagy mediates the mitotic senescence transition. , 2009, Genes & development.
[62] S. Lowe,et al. Eating to exit: autophagy-enabled senescence revealed. , 2009, Genes & development.
[63] Yu Deng,et al. RhoA Regulates G1-S Progression of Gastric Cancer Cells by Modulation of Multiple INK4 Family Tumor Suppressors , 2009, Molecular Cancer Research.
[64] H. Lane,et al. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition , 2009, Molecular Cancer Therapeutics.
[65] N. Hay,et al. Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. , 2009, Seminars in cancer biology.
[66] H. Lane,et al. Increased AKT S 473 phosphorylation after mTORC 1 inhibition is rictor dependent and does not predict tumor cell response to PI 3 K / mTOR inhibition , 2009 .
[67] Jianping Ye,et al. S6K Directly Phosphorylates IRS-1 on Ser-270 to Promote Insulin Resistance in Response to TNF-α Signaling through IKK2* , 2008, Journal of Biological Chemistry.
[68] M. Essers,et al. Interaction of FOXO with β-Catenin Inhibits β-Catenin/T Cell Factor Activity* , 2008, Journal of Biological Chemistry.
[69] Ji-yong Wang,et al. Nuclear Dvl, c-Jun, β-catenin, and TCF form a complex leading to stabiLization of β-catenin–TCF interaction , 2008, The Journal of cell biology.
[70] T. Tsuruo,et al. FOXO transcription factor-dependent p15INK4b and p19INK4d expression , 2008, Oncogene.
[71] A. Giordano,et al. From G0 to S phase: A view of the roles played by the retinoblastoma (Rb) family members in the Rb‐E2F pathway , 2007, Journal of cellular biochemistry.
[72] G. Semenza,et al. Hypoxia-Inducible Factor 1 and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1 , 2007, Molecular and Cellular Biology.
[73] Lewis C. Cantley,et al. AKT/PKB Signaling: Navigating Downstream , 2007, Cell.
[74] A. Lipovsky,et al. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. , 2006, Molecular cell.
[75] J. Baselga,et al. Phosphorylated 4E binding protein 1: A hallmark of cell signaling that correlates with survival in ovarian cancer , 2006, Cancer.
[76] J. Qin,et al. SIN1/MIP1 Maintains rictor-mTOR Complex Integrity and Regulates Akt Phosphorylation and Substrate Specificity , 2006, Cell.
[77] Ming You,et al. TSC2 Integrates Wnt and Energy Signals via a Coordinated Phosphorylation by AMPK and GSK3 to Regulate Cell Growth , 2006, Cell.
[78] Ji Luo,et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.
[79] Eyal Gottlieb,et al. TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.
[80] M. Hall,et al. TOR Signaling in Growth and Metabolism , 2006, Cell.
[81] D. Kwiatkowski,et al. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. , 2005, Human molecular genetics.
[82] F. Liu,et al. PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle. , 2005, American journal of physiology. Endocrinology and metabolism.
[83] J. Martínez,et al. Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma: p53, p21, p16 and p15 , 2005, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[84] Paul Tempst,et al. Phosphorylation and Functional Inactivation of TSC2 by Erk Implications for Tuberous Sclerosisand Cancer Pathogenesis , 2005, Cell.
[85] D. Guertin,et al. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.
[86] R. Nusse,et al. Wnt signaling in disease and in development , 2005, Cell Research.
[87] R. Loewith,et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive , 2004, Nature Cell Biology.
[88] D. Guertin,et al. Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton , 2004, Current Biology.
[89] R. DePinho,et al. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. , 2004, Genes & development.
[90] H. Saya,et al. Down‐regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1‐dependent DNA‐damage checkpoint signals contributes to cell cycle arrest at G1/S transition , 2004, Genes to cells : devoted to molecular & cellular mechanisms.
[91] N. Sonenberg,et al. Signaling from Akt to FRAP/TOR Targets both 4E-BP andS6K in Drosophilamelanogaster , 2003, Molecular and Cellular Biology.
[92] C. Downes,et al. Redox regulation of PI 3‐kinase signalling via inactivation of PTEN , 2003, The EMBO journal.
[93] J. Baselga,et al. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] M. Mita,et al. The Molecular Target of Rapamycin (mTOR) as a Therapeutic Target Against Cancer , 2003, Cancer biology & therapy.
[95] C. Clevenger. Signal transduction. , 2003, Breast disease.
[96] J. Crespo,et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. , 2002, Molecular cell.
[97] K. M. Nicholson,et al. The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.
[98] C. Martínez-A,et al. Forkhead transcription factors contribute to execution of the mitotic programme in mammals , 2001, Nature.
[99] J. Schlessinger. Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.
[100] A. Kimmel,et al. GSK3, a master switch regulating cell-fate specification and tumorigenesis. , 2000, Current opinion in genetics & development.
[101] T. Kurosaki,et al. The Inositol Phosphatase SHIP Inhibits Akt/PKB Activation in B Cells* , 1998, The Journal of Biological Chemistry.
[102] Kevin Ryan,et al. The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 , 1998, The EMBO journal.
[103] J. Massagué. TGF-beta signal transduction. , 1998, Annual review of biochemistry.
[104] P. Cohen,et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα , 1997, Current Biology.
[105] P. Moore,et al. Assignment of the human FKBP12-rapamycin-associated protein (FRAP) gene to chromosome 1p36 by fluorescence in situ hybridization. , 1996, Genomics.
[106] R. Abraham,et al. Immunopharmacology of rapamycin. , 1996, Annual review of immunology.
[107] J. Downward. A target for Pl(3) kinase , 1995, Nature.
[108] J. Downward. Signal transduction. A target for PI(3) kinase. , 1995, Nature.
[109] J. Schlessinger,et al. Signaling by Receptor Tyrosine Kinases , 1993 .
[110] J. Testa,et al. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region. , 1991, Science.
[111] J. Woodgett,et al. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. , 1991, European journal of biochemistry.
[112] R. Weinberg,et al. c‐myc and c‐fos expression in differentiating mouse primary keratinocytes. , 1986, The EMBO journal.
[113] R. Weinberg,et al. Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts , 1986, Molecular and cellular biology.
[114] G. Gill,et al. The EGF receptor: structure, regulation and potential role in malignancy. , 1985, Cancer surveys.
[115] J. Mendelsohn,et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. , 1983, Molecular biology & medicine.
[116] J. Hartley,et al. Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. , 1977, Proceedings of the National Academy of Sciences of the United States of America.
[117] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.